Inovio Pharmaceuticals Inc  

(Public, NASDAQ:INO)   Watch this stock  
Find more results for AMEX:INO
+0.20 (1.75%)
Real-time:   11:14AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.50 - 11.75
52 week 6.52 - 15.80
Open 11.60
Vol / Avg. 335,078.00/1.47M
Mkt cap 702.44M
P/E     -
Div/yield     -
EPS -1.31
Shares 60.40M
Beta 3.13
Inst. own 19%
Nov 4, 2014
Inovio Pharmaceuticals Inc at EBD Group BIO-Europe Conference - 11:45AM EST - Add to calendar
Sep 26, 2014
Inovio Pharmaceuticals Inc at BioCentury Publications NewsMakers in the Biotech Industry
Sep 12, 2014
Inovio Pharmaceuticals Inc at Aegis Capital Corp Healthcare & Technology Conference
Sep 10, 2014
Inovio Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Aug 11, 2014
Q2 2014 Inovio Pharmaceuticals Inc Earnings Release
Aug 11, 2014
Q2 2014 Inovio Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -281.92% -490.69%
Operating margin -267.07% -145.12%
EBITD margin - -139.17%
Return on average assets -29.26% -99.06%
Return on average equity -34.29% -152.12%
Employees 71 -
CDP Score - -


United States - Map
+1-858-5976006 (Phone)
+1-267-4404242 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Inovio Pharmaceuticals, Inc. is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. The Company's clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. As of December 31, 2011 it owned 16.1% interest in VGX Int�l.

Officers and directors

J. Joseph Kim Ph.D. President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Peter D. Kies Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Niranjan Y. Sardesai Ph.D. Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
Jennifer Laux Vice President - Commercial
Bio & Compensation  - Reuters
Mark L. Bagarazzi M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Avtar S. Dhillon M.D. Non-Executive Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 69
Bio & Compensation  - Reuters
Angel Cabrera Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Morton Collins Ph.D. Independent Director
Age: 78
Bio & Compensation  - Reuters
Adel A. F. Mahmoud M.D., Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters